Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2

Hidekazu Tanaka, Michinari Hirata, Satomi Shinonome, Toru Wada, Motofumi Iguchi, Keiji Dohi, Makiko Inoue, Yukichi Ishioka, Kanji Hojo, Tomomi Yamada, Tatsuya Sugimoto, Koichi Masuno, Ken ichi Nezasa, Norihito Sato, Kenji Matsuo, Shuji Yonezawa, Eugene P. Frenkel, Michitaka Shichijo

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) are validated molecular targets in cancer therapy. Dual blockade has been explored and one such agent, lapatinib, is in clinical practice but with modest activity. Through chemical screening, we discovered a novel EGFR and HER2 inhibitor, S-222611, that selectively inhibited both kinases with IC50s below 10 nmol/L. S-222611 also inhibited intracellular kinase activity and the growth of EGFR-expressing and HER2-expressing cancer cells. In addition, S-222611 showed potent antitumor activity over lapatinib in a variety of xenograft models. In evaluations with two patient-oriented models, the intrafemoral implantation model and the intracranial implantation model, S-222611 exhibited excellent activity and could be effective against bone and brain metastasis. Compared to neratinib and afatinib, irreversible EGFR/HER2 inhibitors, S-222611 showed equivalent or slightly weaker antitumor activity but a safer profile. These results indicated that S-222611 is a potent EGFR and HER2 inhibitor with substantially better antitumor activity than lapatinib at clinically relevant doses. Considering the safer profile than for irreversible inhibitors, S-222611 could be an important option in future cancer therapy. S-222611, a novel EGFR/HER2 kinase inhibitor, showed potent antitumor activity in the intracranial implantation model of breast cancer, due to its higher penetration into brain than lapatinib. This supports the potential clinical value of S-222611 for brain metastasis.

Original languageEnglish (US)
Pages (from-to)1040-1048
Number of pages9
JournalCancer Science
Volume105
Issue number8
DOIs
StatePublished - 2014

Fingerprint

Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Brain
Phosphotransferases
Neoplasm Metastasis
human ERBB2 protein
Neoplasms
Heterografts
Breast Neoplasms
Bone and Bones
lapatinib
Therapeutics
Growth

Keywords

  • Antitumor activity
  • Epidermal growth factor receptor
  • Human epidermal growth factor receptor 2
  • Kinase inhibitor
  • S-222611

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2. / Tanaka, Hidekazu; Hirata, Michinari; Shinonome, Satomi; Wada, Toru; Iguchi, Motofumi; Dohi, Keiji; Inoue, Makiko; Ishioka, Yukichi; Hojo, Kanji; Yamada, Tomomi; Sugimoto, Tatsuya; Masuno, Koichi; Nezasa, Ken ichi; Sato, Norihito; Matsuo, Kenji; Yonezawa, Shuji; Frenkel, Eugene P.; Shichijo, Michitaka.

In: Cancer Science, Vol. 105, No. 8, 2014, p. 1040-1048.

Research output: Contribution to journalArticle

Tanaka, H, Hirata, M, Shinonome, S, Wada, T, Iguchi, M, Dohi, K, Inoue, M, Ishioka, Y, Hojo, K, Yamada, T, Sugimoto, T, Masuno, K, Nezasa, KI, Sato, N, Matsuo, K, Yonezawa, S, Frenkel, EP & Shichijo, M 2014, 'Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2', Cancer Science, vol. 105, no. 8, pp. 1040-1048. https://doi.org/10.1111/cas.12449
Tanaka, Hidekazu ; Hirata, Michinari ; Shinonome, Satomi ; Wada, Toru ; Iguchi, Motofumi ; Dohi, Keiji ; Inoue, Makiko ; Ishioka, Yukichi ; Hojo, Kanji ; Yamada, Tomomi ; Sugimoto, Tatsuya ; Masuno, Koichi ; Nezasa, Ken ichi ; Sato, Norihito ; Matsuo, Kenji ; Yonezawa, Shuji ; Frenkel, Eugene P. ; Shichijo, Michitaka. / Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2. In: Cancer Science. 2014 ; Vol. 105, No. 8. pp. 1040-1048.
@article{2561269d31264561983c23bfc6e9fbce,
title = "Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2",
abstract = "Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) are validated molecular targets in cancer therapy. Dual blockade has been explored and one such agent, lapatinib, is in clinical practice but with modest activity. Through chemical screening, we discovered a novel EGFR and HER2 inhibitor, S-222611, that selectively inhibited both kinases with IC50s below 10 nmol/L. S-222611 also inhibited intracellular kinase activity and the growth of EGFR-expressing and HER2-expressing cancer cells. In addition, S-222611 showed potent antitumor activity over lapatinib in a variety of xenograft models. In evaluations with two patient-oriented models, the intrafemoral implantation model and the intracranial implantation model, S-222611 exhibited excellent activity and could be effective against bone and brain metastasis. Compared to neratinib and afatinib, irreversible EGFR/HER2 inhibitors, S-222611 showed equivalent or slightly weaker antitumor activity but a safer profile. These results indicated that S-222611 is a potent EGFR and HER2 inhibitor with substantially better antitumor activity than lapatinib at clinically relevant doses. Considering the safer profile than for irreversible inhibitors, S-222611 could be an important option in future cancer therapy. S-222611, a novel EGFR/HER2 kinase inhibitor, showed potent antitumor activity in the intracranial implantation model of breast cancer, due to its higher penetration into brain than lapatinib. This supports the potential clinical value of S-222611 for brain metastasis.",
keywords = "Antitumor activity, Epidermal growth factor receptor, Human epidermal growth factor receptor 2, Kinase inhibitor, S-222611",
author = "Hidekazu Tanaka and Michinari Hirata and Satomi Shinonome and Toru Wada and Motofumi Iguchi and Keiji Dohi and Makiko Inoue and Yukichi Ishioka and Kanji Hojo and Tomomi Yamada and Tatsuya Sugimoto and Koichi Masuno and Nezasa, {Ken ichi} and Norihito Sato and Kenji Matsuo and Shuji Yonezawa and Frenkel, {Eugene P.} and Michitaka Shichijo",
year = "2014",
doi = "10.1111/cas.12449",
language = "English (US)",
volume = "105",
pages = "1040--1048",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2

AU - Tanaka, Hidekazu

AU - Hirata, Michinari

AU - Shinonome, Satomi

AU - Wada, Toru

AU - Iguchi, Motofumi

AU - Dohi, Keiji

AU - Inoue, Makiko

AU - Ishioka, Yukichi

AU - Hojo, Kanji

AU - Yamada, Tomomi

AU - Sugimoto, Tatsuya

AU - Masuno, Koichi

AU - Nezasa, Ken ichi

AU - Sato, Norihito

AU - Matsuo, Kenji

AU - Yonezawa, Shuji

AU - Frenkel, Eugene P.

AU - Shichijo, Michitaka

PY - 2014

Y1 - 2014

N2 - Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) are validated molecular targets in cancer therapy. Dual blockade has been explored and one such agent, lapatinib, is in clinical practice but with modest activity. Through chemical screening, we discovered a novel EGFR and HER2 inhibitor, S-222611, that selectively inhibited both kinases with IC50s below 10 nmol/L. S-222611 also inhibited intracellular kinase activity and the growth of EGFR-expressing and HER2-expressing cancer cells. In addition, S-222611 showed potent antitumor activity over lapatinib in a variety of xenograft models. In evaluations with two patient-oriented models, the intrafemoral implantation model and the intracranial implantation model, S-222611 exhibited excellent activity and could be effective against bone and brain metastasis. Compared to neratinib and afatinib, irreversible EGFR/HER2 inhibitors, S-222611 showed equivalent or slightly weaker antitumor activity but a safer profile. These results indicated that S-222611 is a potent EGFR and HER2 inhibitor with substantially better antitumor activity than lapatinib at clinically relevant doses. Considering the safer profile than for irreversible inhibitors, S-222611 could be an important option in future cancer therapy. S-222611, a novel EGFR/HER2 kinase inhibitor, showed potent antitumor activity in the intracranial implantation model of breast cancer, due to its higher penetration into brain than lapatinib. This supports the potential clinical value of S-222611 for brain metastasis.

AB - Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) are validated molecular targets in cancer therapy. Dual blockade has been explored and one such agent, lapatinib, is in clinical practice but with modest activity. Through chemical screening, we discovered a novel EGFR and HER2 inhibitor, S-222611, that selectively inhibited both kinases with IC50s below 10 nmol/L. S-222611 also inhibited intracellular kinase activity and the growth of EGFR-expressing and HER2-expressing cancer cells. In addition, S-222611 showed potent antitumor activity over lapatinib in a variety of xenograft models. In evaluations with two patient-oriented models, the intrafemoral implantation model and the intracranial implantation model, S-222611 exhibited excellent activity and could be effective against bone and brain metastasis. Compared to neratinib and afatinib, irreversible EGFR/HER2 inhibitors, S-222611 showed equivalent or slightly weaker antitumor activity but a safer profile. These results indicated that S-222611 is a potent EGFR and HER2 inhibitor with substantially better antitumor activity than lapatinib at clinically relevant doses. Considering the safer profile than for irreversible inhibitors, S-222611 could be an important option in future cancer therapy. S-222611, a novel EGFR/HER2 kinase inhibitor, showed potent antitumor activity in the intracranial implantation model of breast cancer, due to its higher penetration into brain than lapatinib. This supports the potential clinical value of S-222611 for brain metastasis.

KW - Antitumor activity

KW - Epidermal growth factor receptor

KW - Human epidermal growth factor receptor 2

KW - Kinase inhibitor

KW - S-222611

UR - http://www.scopus.com/inward/record.url?scp=84906544683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906544683&partnerID=8YFLogxK

U2 - 10.1111/cas.12449

DO - 10.1111/cas.12449

M3 - Article

C2 - 24837299

AN - SCOPUS:84906544683

VL - 105

SP - 1040

EP - 1048

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 8

ER -